Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

Inclusion Criteria:

- 18 years or older

- type 2 diabetes

- A1c 7.1 - 11

- BMI 25 - 45

- stable weight for 3 months before screening

- fasting glucose < 280 at screening

- stable dose of metformin for at least 2 months before screening

- not being treated with or on a stable dose of hormone replacement therapy, oral
contraceptives, anti-hypertensive agents, lipid lowering agents, thyroid replacement
therapy, anti-depressants, drugs known to affect body weight

- male or female, non-lactating, non-pregnant and willing to use birth control

- lab values that are not clinically significant at screening

- physical exam and ECG that are not clinically significant at screening

- able to read, understand, and sign consent form

Exclusion Criteria:

- liver disease

- renal disease

- cardiovascular disease

- gastroparesis

- cancer within 5 years of screening

- macular edema

- chronic infections

- drug or alcohol abuse

- fasting triglycerides > or = 600 at screening

- previous exposure to exenatide LAR

- has donated blood within 60 days of screening or is planning to donate during the
study

- has had a major surgery or blood transfusion within 2 months before screening

- is currently being treated or is expecting to be treated with Byetta, Januvia, SU,
TZD, GLP-1 analog, alpha-glucosidase inhibitor, meglitinide, nateglinide, symlin,
insulin, systemic corticosteroids, lopid or rifampin

- has received an investigational drug within 1 month before screening

- has allergies or hypersensitivity to any component of the study drug

- has previously had an adverse event related to TZD or Januvia

- is an immediate family member of the study sight or directly affiliated

- is employed by Amylin, Lilly or Alkermes